These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 34387603)

  • 1. Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
    Wu C; Fan M; Hu Y
    Anticancer Drugs; 2022 Jan; 33(1):e734-e737. PubMed ID: 34387603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
    Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
    Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: olaparib use in metastatic lung adenocarcinoma with
    Soon Jian Hao J; Hoai CS; Weng DTS; Ngeow J; Chiang J
    Cold Spring Harb Mol Case Stud; 2022 Dec; 8(7):. PubMed ID: 36577523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    Li M; Mou Y; Hou S; Cao D; Li A
    Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
    Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN
    J Clin Oncol; 2020 Oct; 38(30):3528-3537. PubMed ID: 32749942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P
    N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    Cecere SC; Musacchio L; Bartoletti M; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Naglieri E; Scollo P; Marchetti C; Raspagliesi F; Greggi S; Cinieri S; Bergamini A; Orditura M; Valabrega G; Scambia G; Martinelli F; De Matteis E; Cardalesi C; Loizzi V; Perniola G; Carella C; Scandurra G; Giannone G; Pignata S
    Int J Gynecol Cancer; 2021 Jul; 31(7):1031-1036. PubMed ID: 33990353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    Armstrong AC; Clay V
    Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review.
    Matsubayashi H; Todaka A; Tsushima T; Kiyozumi Y; Harada R; Ishihara E; Higashigawa S; Ohike N; Sakamoto H; Sato J; Ishiwatari H; Sugiura T; Uesaka K
    Fam Cancer; 2024 Aug; 23(3):393-398. PubMed ID: 38733420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
    Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC; Coleman RL; Westin SN
    Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.